Clinical and Molecular Evidence for Association of SLE with parvovirus B19

Lupus

Volumn 19, Issue 7, 2010, Pages 783-792

  Pavlovic, M ^a   Kats, A ^b   Cavallo, M ^b   Shoenfeld, Y ^c  

^a Florida Atlantic Univ   (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmune diseases; Cytokine microarray profiling; Hydrolytic anti DNA autoantibodies; Parvovirus B19; Systemic lupus erythematosus (SLE)

Indexed keywords

ALPHA INTERFERON; APC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYELOID DIFFERENTIATION FACTOR 88; SINGLE STRANDED DNA; TOLL LIKE RECEPTOR 9;

ADENO ASSOCIATED VIRUS; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL CYCLE S PHASE; DISEASE ASSOCIATION; DNA SEQUENCE; GENE SWITCHING; HUMAN; HUMAN PARVOVIRUS B19; HYDROLYSIS; INVERTED TERMINAL REPEAT; NONHUMAN; PARVOVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VIREMIA; VIRUS CAPSID; VIRUS CULTURE; VIRUS MORPHOLOGY; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; ANIMALS; AUTOANTIBODIES; CHILD; DNA, SINGLE-STRANDED; DNA, VIRAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; TOLL-LIKE RECEPTOR 9; VIRAL VACCINES;

EID: 77952899400     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310365715     Document Type: Review

References (95)

1. Sun Y., Fong KY, Chung MC, Yao ZJ Peptide mimicking antigenic and immunogenic epitope of double-stranded DNA in systemic lupus erythematosus. Int Immunol 2001 ; 13: 223-232.
2. Luger D., Dayan M., Zinger H., Liu JP, Moses E. A peptide based on a complementarity determining region of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004 ; 24: 579-590.
3. Harley JB, James JA Epstein-Barr virus infection induces lupus autoimmunity. Bull NYU Hospital Joint Diseases 2006 ; 64: 1-2.
4. Lewis RM, Andre-Schwartz J., Harbis GS, Hirsch MS, Black PH, Schwartz RS Canine systemic lupus erythematosus. Transmission of serologic abnormalities by cell-free filtrates. J Clin Invest 1973 ; 52: 1893-1907.
5. Magro CM, Nuovo G., Ferri C., Crowson AN, Giuggioli D., Sebastiani M. Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma. J Cutan Pathol 2004 ; 31: 43-50.
6. Hsu TC, Tsau GJ Human parvovirus B19 infection in patients with SLE. Rheumatology (Oxford) 2001 ; 40: 152-157.
7. Mehraein Y., Lennerz C., Ehlhardt S. Detection of parvovirus B19 capsid proteins in lymphocytic cells in synovial tissue of autoimmune chronic arthritis. Mod Pathol 2003 ; 16: 811-817.
8. Crowson AN, Magro CM, Dawood MR A causal role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes. J Cutan Pathol 2000 ; 27: 505-515.
9. Crow MK Interferon pathway activation in systemic lupus erythematosus. Curr Rheumatol Rep 2005 ; 7: 463-468.
10. Berghofer B., Frommer T., Haley G., Fink L., Bein G., Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J Immunol 2006 ; 177: 2088-2096.
11. Dorsch S., Liebisch G., Kaufmann B., et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. Virol 2002 ; 76: 2014-2018.
12. Li Y., Zadori Z., Bando H., et al. Genome organization of the densovirus from Bombyx mori (BmDNV-1) and enzyme activity of its capsid. J Gen Virol 2001 ; 82: 2821-2825.
13. Metzger J., von Landenberg P., Kehrel M., Buhl A., Lackner KJ, Luppa PB Biosensor analysis of beta2-glycoprotein I-reactive autoantibodies: evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies. Clin Chem 2007 ; 53: 1137-1143.
14. von Landenberg P., Lehmann HW, Modrow S. Human parvovirus B19 infection and antiphospholipid antibodies. Autoimmun Rev 2007 ; 6: 278-285. (Pubitemid 46507992)
15. Lehmann HW, Plentz A., von Landenberg P., Muller-Godeffroy E., Modrow S. Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies. Arthritis Res Ther 2004 ; 6: R1 - R6.
16. Lehmann HW, von Landenberg P., Modrow S. Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2003 ; 2: 218-223.
17. von Landenberg P., Lehmann HW, Knoll A., Dorsch S., Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 2003 ; 48: 1939-1947.
18. Zandmand-Goddard G., Shoenfeld Y. SLE. Infection and Autoimmunity. Amsterdam: Elsevier ; 2004. p. 491-503.
19. Severin MC, Shoenfeld Y. In: Shoenfeld Y, Roese NR (eds), Parvovirus B19 Infection and its Association to Autoimmune disease. Infection and Autoimmunity. Amsterdam: Elsevier; 2004. p. 181-188.
20. Hayakawa H., Tara M., Nina K., Osame M. A clinical study of adult human Parvovirus B19 infection. Intern Med 2002 ; 41: 295-299.
21. Severin MC, Levy Y., Shoenfled Y. Systemic lupus erythematosus and parvovirus B19; causal coincidence or causative culprit? Clin Rev Allergy Immunol 2003 ; 25: 41-48.
22. Sun Y., Chen AY, Cheng F., et al. Molecular characterization of the minute virus of canines reveals unique features of bocaviruses. J Virol 2009 ; 83: 3956-3967.
23. Modrow S., Lowin T., Mo BSM, Broker M. Modified VP1 capsid protein of parvovirus B19. Patent # IPN: WO2006/032647 A3, 2006.
24. Heeggaard E., Brown KE Human parvovirus B19. Clin Microbiol Rev 2002 ; 15: 485-505.
25. Brown KE, Hibbs JR, Gallinella G., et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994 ; 330: 1193-1196.
26. http://www.aafp.org/afp/20041115/tips/5.html (accessed 2009).
27. Hokynar K., Brunstein J., Soderlund-Venermo M., et al. Integrity and full coding sequence of B19 virus DNA persisting in human synovial tissue. J Gen Virol 2000 ; 81: 1017-1025.
28. Erdman DD, Durigon EL, Wang QY, Anderson LJ Genetic diversity of human parvovirus B19; sequence analysis of the VP1/VP2 gene from multiple isolates. J Gen Virol 1996 ; 11: 2767-2774.
29. Girod A., Wobus CE, Zadori Z. The VP1 capsid protein of adenoassociated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 2002 ; 83: 973-978.
30. Kerr JR, Bracell J., Liang I., et al. Chronic fatigue syndrome and arthralgia following parvovirus B19 infection. J Rheumatol 2002 ; 29: 595-602.
31. Pavlovic M., Chen R., Kats AM, et al. Highly specific novel method for isolation and purification of lupus anti-DNA antibody via oligo-(dT) magnetic beads. Ann NY Acad Sci 2007 ; 1108: 203-217.
32. Kats AM Pavlovic M., Cavallo MF, Chen R., Mari F., Hartmann JX Subclass determination of lupus anti-DNA antibodies obtained by two different purification methods. In: Autoimmunity Reviews: Abstracts of 5th International Congress on Autoimmunity, Porto, Portugal, 10-14 September 2008.
33. Pavlovic M. The role of anti-DNA antibodies in systemic lupus erythematosus: ranges and perspectives. MDMedical Data Medical Review 2009 ; 1, 1: 7-11.
34. Shoenfeld Y., Toubi E. Protective autoantibodies. Arthritis Rheum 2005 ; 52: 2599-2606.
35. Heegaard ED, Petersen BL, Heillmann CJ, Hornsleth A. Prevalence of parvovirus B19 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J Clin Microbiol 2002 ; 40: 933-936.
36. Greener M. Human parvovirus B19 persists in adult liver. J Med Virol 2001 ; 65: 395-401.
37. Oakley J., Unpublished notes. www.medynet.com/usarios/nnuneza/virologia/ parvoviruses.htm (accessed 2009).
38. Karl G., Panzinger B., Dobmann S., Steigerwald R., Emrich T. Quantification of Parvovirus B19 in research samples by real-time on-line PCR with the light cycler. Biochemica 2002 ; 1: 10-11.
39. Smitest. Parvovirus B19 DNA detection kit. Product Code: GS-B0501. Genome Science Laboratories, Co. Ltd., 2002, p. 1-12.
40. Yu Mei-ying W. Parvovirus B19 NAT for whole blood and source plasma. In: 75th Blood Products Advisory Committee Meeting, 12 December 2002, p.1-4.
41. Schwarz TF, Serke S., Hottentrager B., et al. Replication of parvovirus B19 in hematopoietic progenitor cells generated in vitro from normal human peripheral blood. J Virol 1992 ; 66: 1273-1276.
42. Rahav G. Parvovirus B19 infection-an emerging infectious disease? IMAJ 2002 ; 810-811.
43. Blümel J., Schmidt I., Willkommen H., Lower J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002 ; 42: 1011-1018.
44. Ozawa K., Kurtzman G., Young N. Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro. Blood 1987 ; 70: 384-391.
45. Brown KE, Mori J., Cohen BJ, Field AM In vitro propagation of parvovirus B19 in primary foetal liver culture. J Gen Virol 1991 ; 72: 741-745.
46. Dewhurst S. at: http:/path.upmc.edu/cases/case522/images/Table-1.gif (accessed 2009).
47. Sosa CE, Mahoney JB, Luinstra KE, Sternbach M., Chernesky MA Replication and cytopathology of human parvovirus B19 in human umbilical cord blood erythroid progenitor cells. J Med Virol 1992 ; 36: 125-130.
48. Munshi NC, Zhou S., Woody MJ, Morgan DA, Srivastava A. Successful replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02. J Virol 1993 ; 67: 562-566.
49. Shimomura S., Komatsu N., Frickhofen N., Anderson S., Kajigaya S., Young NS First continuous propagation of B19 parvovirus in a cell line. Blood 1992 ; 79: 18-24.
50. Takahashi T., Ozawa K., Takahashi K., et al. DNA replication of parvovirus B 19 in a human elytroid leukemia cell line (JK-1) in vitro. Arch Viral 1993 ; 131: 201-208.
51. Niagara E., Yoshida T., Takahashi H., et al. Infection of the elytroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity. J Viral Methods 1999 ; 83: 45-54.
52. Bostic JR, Brown KE, Young NS, Koenig S. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay. J Infect Dis 1999 ; 179: 619-626.
53. Srivastava A. Recombinant human Parvovirus B19 vectors. Pathol Biol 2002 ; 50: 295-306.
54. Fields BN Fields Virology Third Edition. Philadelphia, PA: Lippincott-Raven Publishers ; 1996. p. 2199-2220.
55. Sevall SJ Parvovirus B19. www.specialtylabs.com
56. Pallier C., Greco A., Le Junter J., Saib A., Vassias I., Morinet F. The 3' untranslated region of the B19 parvovirus capsid protein mRNAs inhibits its own mRNA translation in nonpermissive cells. J Virol 1997 ; 71: 9482-9489.
57. Ponnazhagan S., Woody MJ, Wang XS, Zhou ZS, Srivastava A. Transcriptional transactivation of parvovirus B19 promoters in nonpermissive human cells by adenovirus type2. J Virol 1995 ; 69: 8096-8101.
58. Hiroshi C., Morita M., Murata K., et al. A transgenic mouse model for non-immune hydrops fetalis induced by the NS1 gene of human parvovirus B19. J Gen Virol 2002 ; 83: 273-281.
59. Alexandrova R., Shikova E. Parvovirus B19. Exp Pathol Parasitol 1999 ; 3: 38-44.
60. Brunstein J., Astell CR Analysis of the internal replication sequence indicates that there are three elements required for efficient replication of minute virus of mice menigenomes. J Virol 1997 ; 71: 9087-9095.
61. Hemauer A., von Poblotzki A., Gigler A., et al. Sequence variability among different parvovirus B19 isolates. J Gen Virol 1996 ; 77: 1781-1785.
62. Mori J., Beattie P., Melton DW, Cohen BJ, Clewed JP Structure and mapping of the DNA of human parvovirus B19. J Gen Virol 1987 ; 68: 2797-2806.
63. Umene K., Nunoue T. The genome type of human parvovirus B19 strains isolated in Japan during 1981 differs from types detected in 1986 to 1987: a correlation between genome type and prevalence. J Gen Virol 1990 ; 71: 983-986.
64. Shade RO, Blundell MC, Cotmore SF, Tattersall P., Astell CR Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 1986 ; 58: 921-936.
65. Nguyen QT, Sifer C., Schneider V., Bernaudin F., Auguste V., Garbarg-Chenon A. Detection of an erythrovirus sequence distinct from B19 in a child with acute anemia. Lancet 1998 ; 352: 1524.
66. Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: Erythrocyte p antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 2001 ; 75: 4110-4116.
67. Brown KE, Anderson SM, Young NS Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993 ; 262: 114-117.
68. Liu JM, Green SW, Shimada T., Young NS A block in full-length transcript maturation in cells nonpermissive for B19 parvovirus. J Virol 1992 ; 66: 4686-4692.
69. Weigel-Kelley KA, Yoder MC, Srivastava A. α5β integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of β1 integrin for viral entry. Blood 2003 ; 102: 3927-3933.
70. Vihinen-Ranta M., Yuan W., Parrish CR Cytoplasmic trafficking of the canine parvovirus capsid and its role in infection and nuclear transport. J Virol 2000 ; 74: 4853-4859.
71. Wandstrat AE, Carr-Johnson F., Branch V., et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun 2006 ; 27: 153-160.
72. Li QZ, Zhou J., Wandstrat AE, et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol 2007 ; 147: 60-70.
73. Mandel M., Achiron A. Gene expression studies in SLE. Lupus 2006 ; 15: 451-456.
74. Koichi O., Tsutomu O., Ryo M., et al. Case of drug-induced hypersensitivity syndrome (DIHS) with the reactivation of parvovirus B19 infection. J Saitama Children's Med Center 2006 ; 22: 111-115.
75. Hemauer A., Beckenlehner K., Wolf H., Lang B., Modrow S. Acute parvoviruB19 infection with a flare of systemic lupus erythematosus in a female patient. J Clin Virol 1999 ; 14: 73-77.
76. Langartner J., Andus T., Hemauer A., Scholmerich J., Lang B. Imitation of an acute exacerbation of established systemic lupus erythematosus caused by Parvovirus B19 infection. Dtsch Med Wochenschr 1999 ; 124: 859-862. (Pubitemid 29336931)
77. Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 2003 ; 70: 6-11.
78. Bengtsson A., Widell A., Elmståhl S., Sturfelt G. No serological indications that systemic lupus erythematosus is linked with exposure to human parvovirus B19. Ann Rheum Dis 2000 ; 59: 64-66.
79. Saeki T., Shibuya M., Sawada H., et al. Human Parvovirus B19 infection mimicking systemic lupus erythematosus. Mod Rheumatol 2001 ; 11: 308-313.
80. Negro A., Regolisti G., Perazzoli F., Coghi P., Tumiati B., Rossi E. Human parvovirus B19 mimicking lupus erythematosus in adult patient. Ann Ital Med Int 2001 ; 161: 25-27.
81. Yaegashi N., Shiraishi H., Takeshihta T., Nakamura M., Yajima A., Sugamura K. Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J Virol 1989 ; 63: 2422-2426.
82. Swanson PC, Ackroyd C., Glick GD Ligand recognition by anti-DNA Autoantibodies. Affinity, specificity and mode of binding. Biochemistry 1996 ; 35: 1624-1633.
83. Teodorescu M. Clinical value of anti-ssDNA (denatured DNA) autoantibody test; beauty is in the eyes of the beholder. Clin Appl Immunol Rev 2001 ; 2: 115-128.
84. Rodkey LS, Gololobov G., Rumbley CA, et al. DNA Hydrolysis by monoclonal autoantibody BV 04-01. Appl Biochem Biotechnol 2000 ; 83: 95-103.
85. Tanner JJ, Komissarov AA, Deutcher SL Crystal structure of an antigen-binding fragment bound to single-stranded DNA. J Molecular Biol 2001 ; 314: 807-822.
86. Cavallo MF, Hartmann JX, Pavlovic M. Real time fluorescence assay for anti-DNA hydrolytic activity. US provisional patent application 60/659, 882, 3 October 2005.
87. Chen R. A. Novel Approach to the Study of Anti-DNA Autoantibody from Human Sera. MS Thesis, Florida Atlantic University, 2004.
88. Ruiz-Argueles A., Rivadeneyra-Espinoza L., Alarcon-Segovia D. Antibody penetration into living cells: pathogenic, preventive and immuno-therapeutic implications. Curr Pharmaceut Design 2003 ; 9: 1881-1887.
89. Pavlovic M., Kats A., Cavallo M., Chen R., Hartmann JX Real-time fluorescent novel developed method for detection and monitoring of hydrolytic activities of Lupus anti-DNA antibodies. Oral presentation. In: Autoimmunity Reviews; Abstracts of the 5th International Congress on Autoimmunity, Porto, Portugal, 10-14 September, 2008.
90. Christenesen SR, Kashgarian M., Alexopoulou L., Flavell RA, Akira S., Shlomichik MJ Toll-like receptor 9 controls ant-DNA auto antibody production in murine lupus. JWM 2005 ; 202: 321-331.
91. Pahl HL Activators and target genes of Rel/NF-kB transcription factors. Oncogene 1999 ; 18: 6853-6866.
92. Ehlers M., Fukujama H., Grasi T., McGaha TL, Aderem A., Ravetch JV TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2 b autoantibodies in SLE. The Journal of Experimental Medicine 2006 ; 203: 553-561.
93. Lleo A., Selmi C., Invernizzi P., Podda M., Gershwin ME The consequences of apoptosis in autoimmunity. J Autoimmune 2008 ; 31 (3). 257-262.
94. Beckingham JA, Cleary J., Bobeck M., Glick GD Kinetic analysis of sequence-specific recognition of ssDNA by an autoantibody. Biochemistry 2003 ; 42: 4118-4126. (Pubitemid 36418305)
95. Meridian Life Science, Inc. Development of a Recombinant Human Parvovirus B19 Vaccine to Prevent Aplastic Crisis. Meridian Life Science, Inc., 2008.